AR128564A1 - Anticuerpos - Google Patents

Anticuerpos

Info

Publication number
AR128564A1
AR128564A1 ARP230100391A ARP230100391A AR128564A1 AR 128564 A1 AR128564 A1 AR 128564A1 AR P230100391 A ARP230100391 A AR P230100391A AR P230100391 A ARP230100391 A AR P230100391A AR 128564 A1 AR128564 A1 AR 128564A1
Authority
AR
Argentina
Prior art keywords
coronavirus
antibody
cov
sars
spike protein
Prior art date
Application number
ARP230100391A
Other languages
English (en)
Inventor
Gavin Screaton
Juthathip Mongkolsapaya
Original Assignee
Rq Biotechnology Ltd
Univ Oxford Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2202232.1A external-priority patent/GB202202232D0/en
Priority claimed from GBGB2203423.5A external-priority patent/GB202203423D0/en
Priority claimed from GBGB2212470.5A external-priority patent/GB202212470D0/en
Priority claimed from GBGB2214036.2A external-priority patent/GB202214036D0/en
Priority claimed from GBGB2215418.1A external-priority patent/GB202215418D0/en
Priority claimed from GBGB2301959.9A external-priority patent/GB202301959D0/en
Application filed by Rq Biotechnology Ltd, Univ Oxford Innovation Ltd filed Critical Rq Biotechnology Ltd
Publication of AR128564A1 publication Critical patent/AR128564A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La invención se refiere a anticuerpos útiles para la prevención, el tratamiento y/o el diagnóstico de infecciones por coronavirus, y enfermedades y/o complicaciones asociadas con infecciones por coronavirus, incluido COVID-19. En particular, la invención se refiere a anticuerpos capaces de unirse a la proteína de la espícula de coronavirus SARS-CoV-2 y a usos de los mismos. Reivindicación 1: Un anticuerpo que puede unirse a la proteína de la espícula del coronavirus SARS-CoV-2, en el que el anticuerpo comprende al menos tres CDR del anticuerpo Omi12, o de uno cualquiera de los 27 anticuerpos en la Tabla 3. Reivindicación 26: Un anticuerpo derivado de la cadena pesada de la línea germinal IGHV1-58, que puede unirse a la proteína de la espícula del coronavirus SARS-CoV-2, en el que el aminoácido en la posición 58 en la región variable de cadena pesada de acuerdo con la numeración de IMGT es prolina o está sustituido con prolina. Reivindicación 28: Un anticuerpo que puede unirse a la proteína de la espícula del coronavirus SARS-CoV-2 que comprende un dominio variable de cadena pesada que comprende una secuencia de aminoácidos que tiene &
ARP230100391A 2022-02-18 2023-02-17 Anticuerpos AR128564A1 (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB2202232.1A GB202202232D0 (en) 2022-02-18 2022-02-18 Antibodies
GBGB2203423.5A GB202203423D0 (en) 2022-03-11 2022-03-11 Antibodies
GB202206777 2022-05-09
GBGB2212470.5A GB202212470D0 (en) 2022-08-26 2022-08-26 Antibodies
GBGB2214036.2A GB202214036D0 (en) 2022-09-26 2022-09-26 Antibodies
GBGB2215418.1A GB202215418D0 (en) 2022-10-18 2022-10-18 Antibodies
GBGB2301959.9A GB202301959D0 (en) 2023-02-10 2023-02-10 Antibodies

Publications (1)

Publication Number Publication Date
AR128564A1 true AR128564A1 (es) 2024-05-22

Family

ID=85283974

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230100391A AR128564A1 (es) 2022-02-18 2023-02-17 Anticuerpos

Country Status (19)

Country Link
US (2) US12030927B2 (es)
EP (1) EP4230650B1 (es)
AR (1) AR128564A1 (es)
CL (1) CL2024002462A1 (es)
DK (1) DK4230650T3 (es)
ES (1) ES3012638T3 (es)
FI (1) FI4230650T3 (es)
HR (1) HRP20250103T1 (es)
HU (1) HUE070285T2 (es)
LT (1) LT4230650T (es)
MA (1) MA61946B1 (es)
PL (1) PL4230650T3 (es)
PT (1) PT4230650T (es)
RS (1) RS66591B1 (es)
SI (1) SI4230650T1 (es)
SM (1) SMT202500056T1 (es)
TW (1) TW202342510A (es)
UY (1) UY40153A (es)
WO (1) WO2023156636A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20240182T1 (hr) 2020-03-26 2024-04-26 Vanderbilt University Ljudska monoklonska protutijela za teški akutni respiratorni sindrom koronavirusa 2 (sars-cov-2)
US20250289871A1 (en) 2022-04-29 2025-09-18 Astrazeneca Uk Limited Sars-cov-2 antibodies and methods of using the same
GB202304512D0 (en) * 2023-03-28 2023-05-10 Univ Oxford Innovation Ltd Antibodies

Family Cites Families (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4122427A (en) 1976-06-24 1978-10-24 Herbert Karsh Motion monitor
JPS58188433A (ja) 1982-04-28 1983-11-02 アロカ株式会社 超音波診断装置
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
EP0216846B2 (en) 1985-04-01 1995-04-26 Celltech Limited Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5088498A (en) 1988-10-17 1992-02-18 The Board Of Regents Of The University Of Washington Ultrasonic plethysmograph
JPH03151944A (ja) 1989-11-08 1991-06-28 Hitachi Medical Corp パルスドプラ計測装置
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
JPH0767451B2 (ja) 1991-12-24 1995-07-26 アロカ株式会社 超音波組織変位計測装置
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5638824A (en) 1993-02-25 1997-06-17 Advanced Monitors Holdings Limited Ultrasonic monitor
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
WO1995015982A2 (en) 1993-12-08 1995-06-15 Genzyme Corporation Process for generating specific antibodies
DE69534347T2 (de) 1994-01-31 2006-05-24 Trustees Of Boston University, Boston Bibliotheken aus Polyklonalen Antikörpern
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5573012A (en) 1994-08-09 1996-11-12 The Regents Of The University Of California Body monitoring and imaging apparatus and method
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
DE19914455B4 (de) 1999-03-30 2005-07-14 Siemens Ag Verfahren zur Bestimmung der Bewegung eines Organs oder Therapiegebiets eines Patienten sowie hierfür geeignetes System
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
EP1229125A4 (en) 1999-10-19 2005-06-01 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING A POLYPEPTIDE
US20060228364A1 (en) 1999-12-24 2006-10-12 Genentech, Inc. Serum albumin binding peptides for tumor targeting
ES2252261T3 (es) 2000-06-28 2006-05-16 Glycofi, Inc. Metodos para producir glicoproteinas modificadas.
CA2424977C (en) 2000-10-06 2008-03-18 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CA2953239A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kirin Co., Ltd. Antibody composition-producing cell
ES2193030T3 (es) 2000-11-22 2003-11-01 Brainlab Ag Metodo para determinar el volumen de los pulmones.
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
NZ571596A (en) 2001-08-03 2010-11-26 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
CN101613705A (zh) 2002-03-19 2009-12-30 国际植物研究所 在植物中优化聚糖生成
US20040014194A1 (en) 2002-03-27 2004-01-22 Schering Corporation Beta-secretase crystals and methods for preparing and using the same
US8814793B2 (en) 2002-12-03 2014-08-26 Neorad As Respiration monitor
GB2396012B (en) 2002-12-03 2006-03-15 Neorad As Respiration monitor
EP2248892B1 (en) 2003-01-22 2015-04-22 Roche Glycart AG Fusion constructs and use of same to produce antibodies with increased FC receptor binding affinity and effector function
US6932769B2 (en) 2003-05-28 2005-08-23 Delphi Technologies, Inc. Ultrasonic occupant detection and classification system
AR047692A1 (es) 2003-07-10 2006-02-08 Epix Medical Inc Imagenes de blancos estacionarios
WO2007001352A2 (en) 2004-08-31 2007-01-04 University Of Washington Ultrasonic technique for assessing wall vibrations in stenosed blood vessels
DE112005002577T5 (de) 2004-10-18 2007-09-20 Kabushiki Kaisha Toshiba Atmungs-Überwachungs-Gerät, Atmungs-Überwachungs-System, medizinisches Verarbeitungssystem, Atmungs-Überwachungs-Verfahren und Atmungs-Überwachungs-Programm
WO2006057911A2 (en) 2004-11-22 2006-06-01 Civco Medical Instruments Co., Inc. Real time ultrasound monitoring of the motion of internal structures during respiration for control of therapy delivery
BRPI0611445A2 (pt) 2005-05-09 2010-09-08 Glycart Biotechnology Ag molécula de ligação a antìgeno glicomanipulada, polinucleotìdeo, polipeptìdeo, vetor, célula hospedeira, método para produção, uso e composição farmacêutica
US20060285071A1 (en) 2005-06-21 2006-12-21 Bausch & Lomb Incorporated Femtosecond laser micromachining of a contact lens and a contact lens manufactured thereby
WO2007032329A1 (ja) 2005-09-14 2007-03-22 Matsushita Electric Industrial Co., Ltd. 位置追跡方法、位置追跡装置および超音波診断装置
JP2009526520A (ja) 2006-01-17 2009-07-23 バイオレックス セラピュティックス インク 植物中でのｎ−グリカンのヒト化及び最適化のための組成物及び方法
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
RU2009116246A (ru) 2006-09-29 2010-11-10 Конинклейке Филипс Электроникс Н.В. (Nl) Способ и устройство для ультразвукового исследования, оставляющее руки свободными
US20090048518A1 (en) 2006-12-10 2009-02-19 Cardio Art Technologies Ltd. Doppler motion sensor apparatus and method of using same
US8591886B2 (en) 2007-07-12 2013-11-26 Gitr, Inc. Combination therapies employing GITR binding molecules
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP3124497B1 (en) 2007-09-14 2020-04-15 Adimab, LLC Rationally designed, synthetic antibody libraries and uses therefor
US10398393B2 (en) 2007-10-02 2019-09-03 Stryker European Holdings I, Llc Dynamic reference method and system for interventional procedures
WO2014152463A1 (en) 2013-03-15 2014-09-25 Cyberheart, Inc. Apparatus and method for real-time tracking of tissue structures
EP2242768A4 (en) 2008-01-17 2012-03-14 Humabs Llc CROSS-NEUTRALIZATION OF HUMAN MONOCLONAL ANTIBODIES AGAINST SARS-COV AND METHODS FOR THEIR APPLICATION
GB2476623B (en) 2008-11-06 2012-11-28 Neorad As Extravasation detection for fluid injection using dopppler ultrasound blood flow measurement
CN104119438A (zh) 2009-01-29 2014-10-29 米迪缪尼有限公司 延长体内半衰期的人抗il-6抗体及其在治疗肿瘤、自身免疫性疾病和炎症性疾病中的应用
CN102469957B (zh) 2009-07-20 2015-09-30 皇家飞利浦电子股份有限公司 用于操作监测系统的方法
US20110121996A1 (en) 2009-11-23 2011-05-26 Delphi Technologies, Inc. Method and System for Detecting an Occupant Using Reflected Signals
US20110208060A1 (en) 2010-02-24 2011-08-25 Haase Wayne C Non-contact Biometric Monitor
JP5492606B2 (ja) 2010-03-03 2014-05-14 アズビル株式会社 演算装置、及び演算装置を備えた流量計
GB2479930B (en) 2010-04-29 2017-12-06 Respinor As Coupling an ultrasound probe to the skin
BR112012027828A2 (pt) 2010-05-03 2016-08-09 Genentech Inc composição de matéria, artigo de fabricação e método de redução da viscosidade de uma formulação contendo proteína e de preparação de uma formulação aquosa contendo proteína
KR102318383B1 (ko) 2010-07-16 2021-10-27 아디맵 엘엘씨 항체 라이브러리
ES2660013T3 (es) 2010-08-13 2018-03-20 Respiratory Motion, Inc. Dispositivos y métodos para la monitorización de la variación respiratoria mediante la medición de volúmenes respiratorios, movimiento y variabilidad
ES2692268T5 (en) 2011-03-29 2025-02-26 Roche Glycart Ag Antibody fc variants
WO2012142031A1 (en) 2011-04-12 2012-10-18 Brigham And Women's Hospital, Inc. System and method for motion tracking using unique ultrasound echo signatures
US20130030285A1 (en) 2011-07-26 2013-01-31 General Electric Company System and method for integrating multiple data sources into an x-ray image referential
MY170569A (en) 2011-08-22 2019-08-19 ResMed Pty Ltd Ultrasonic welding of fabrics for sleep apnea treatment
JP5950517B2 (ja) 2011-09-02 2016-07-13 キヤノン株式会社 被検体情報取得装置、被検体情報取得方法、及びプログラム
US10011660B2 (en) 2012-04-30 2018-07-03 Medimmune, Llc Molecules with reduced effector function and extended half-lives, compositions, and uses thereof
WO2013169338A1 (en) 2012-05-11 2013-11-14 Medimmune, Llc Ctla-4 variants
JP6096459B2 (ja) 2012-10-04 2017-03-15 東芝メディカルシステムズ株式会社 超音波診断装置
BR112015016804A2 (pt) 2013-01-17 2017-07-11 Koninklijke Philips Nv método para reduzir o efeito de movimento fisiológico nos dados de imagens capturados de uma sequência de imagens médicas de um indivíduo, e método para reduzir o efeito do movimento respiratório em dados de imagem de uma sequência de imagens no tempo de ultrassom que serão usados para produzir uma curva da intensidade em função do tempo
KR20140105103A (ko) 2013-02-21 2014-09-01 삼성전자주식회사 장기의 움직임을 추적하는 방법, 장치 및 의료 영상 시스템
CN103584847B (zh) 2013-11-06 2015-04-22 中国人民解放军第三军医大学 一种非接触磁感应心率和呼吸率同步检测方法及系统
JP2015159934A (ja) 2014-02-27 2015-09-07 セイコーエプソン株式会社 超音波計測装置及び超音波計測方法
CN103948401A (zh) 2014-05-20 2014-07-30 夏云 一种便携式肺功能仪器及肺功能检测方法
JO3701B1 (ar) 2014-05-23 2021-01-31 Regeneron Pharma مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
CA2959571A1 (en) 2014-09-03 2016-03-10 Medimmune Limited Stable anti-il-4r-alpha antibody formulation
CN104840218B (zh) 2015-06-09 2018-08-10 联想(北京)有限公司 一种呼吸速率的测量方法及电子设备
GB201519985D0 (en) 2015-11-12 2015-12-30 Respinor As Ultrasonic method and apparatus for respiration monitoring
CN109863174B (zh) 2016-04-29 2023-06-23 维埃拉生物股份有限公司 对FcγRIIA具有特异性的结合分子及其使用
TWI761453B (zh) 2017-03-01 2022-04-21 英商梅迪繆思有限公司 抗rsv單株抗體配製物
WO2020061159A1 (en) 2018-09-20 2020-03-26 Vanderbilt University Human antibodies to zika virus
JP2023512684A (ja) 2020-02-03 2023-03-28 ヴィア・バイオテクノロジー・インコーポレイテッド Ｓａｒｓ－ｃｏｖ－２に対する抗体およびそれを使用する方法
JP2023519105A (ja) 2020-02-11 2023-05-10 ヴァンダービルト ユニバーシティ 重症急性呼吸器症候群コロナウイルス２（ｓａｒｓ－ｃｏｖ－２）に対するヒトモノクローナル抗体
BR112022017048A2 (pt) 2020-02-26 2022-11-16 Vir Biotechnology Inc Anticorpos contra sars-cov-2 e métodos para usar os mesmos
MX2022011142A (es) 2020-03-09 2022-12-13 Abcellera Biologics Inc Anticuerpos anti-coronavirus y metodos de uso.
US11053304B1 (en) 2020-03-23 2021-07-06 Centivax, Inc. Anti-SARS-Cov-2 antibodies derived from 6nb6
HRP20240182T1 (hr) 2020-03-26 2024-04-26 Vanderbilt University Ljudska monoklonska protutijela za teški akutni respiratorni sindrom koronavirusa 2 (sars-cov-2)
KR20250107297A (ko) 2020-04-02 2025-07-11 리제너론 파아마슈티컬스, 인크. 항-sars-cov-2 스파이크 당단백질 항체 및 항원-결합 단편
WO2021203053A1 (en) 2020-04-03 2021-10-07 Vir Biotechnology, Inc. Immunotherapy targeting a conserved region in sars coronaviruses
MX2021015024A (es) * 2020-04-28 2022-01-18 Univ Rockefeller Anticuerpos anti-sars-cov-2 ampliamente neutralizantes y métodos de uso de los mismos.
WO2021231237A2 (en) * 2020-05-11 2021-11-18 Augmenta Bioworks, Inc. Antibodies for sars-cov-2 and uses thereof
TW202208423A (zh) 2020-05-17 2022-03-01 英商阿斯特捷利康英國股份有限公司 Ｓａｒｓ－ｃｏｖ－２抗體及其選擇和使用方法
WO2022026475A2 (en) 2020-07-27 2022-02-03 Igm Biosciences, Inc. Multimeric coronavirus binding molecules and uses thereof
US20220041694A1 (en) 2020-08-10 2022-02-10 Astrazeneca Uk Limited Sars-cov-2 antibodies for treatment and prevention of covid-19
KR20220020228A (ko) 2020-08-11 2022-02-18 (주)셀트리온 안정한 약제학적 제제
EP4288153A1 (en) * 2021-02-04 2023-12-13 RQ Biotechnology Limited Antibodies
TW202342095A (zh) 2021-11-05 2023-11-01 英商阿斯特捷利康英國股份有限公司 用於治療和預防ｃｏｖｉｄ—１９之組成物
WO2023084055A1 (en) 2021-11-12 2023-05-19 Rq Biotechnology Limited Compositions

Also Published As

Publication number Publication date
SI4230650T1 (sl) 2025-06-30
DK4230650T3 (da) 2025-02-10
WO2023156636A1 (en) 2023-08-24
FI4230650T3 (fi) 2025-02-12
US12030927B2 (en) 2024-07-09
EP4230650A1 (en) 2023-08-23
PT4230650T (pt) 2025-02-13
TW202342510A (zh) 2023-11-01
PL4230650T3 (pl) 2025-04-28
EP4230650B1 (en) 2024-11-13
RS66591B1 (sr) 2025-04-30
HRP20250103T1 (hr) 2025-03-28
CL2024002462A1 (es) 2025-01-24
ES3012638T3 (en) 2025-04-09
MA61946B1 (fr) 2025-04-30
LT4230650T (lt) 2025-03-10
HUE070285T2 (hu) 2025-05-28
US20230265170A1 (en) 2023-08-24
UY40153A (es) 2023-09-15
SMT202500056T1 (it) 2025-03-12
US20240376178A1 (en) 2024-11-14

Similar Documents

Publication Publication Date Title
AR128564A1 (es) Anticuerpos
BR112021013337A2 (pt) Proteínas de ligação a patógenos
PE20181805A1 (es) Composiciones y anticuerpos anti-tim-3
WO2021156490A3 (en) Corona virus binders
EA201491571A1 (ru) МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С АСИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ
PE20200294A1 (es) Anticuerpos que se unen especificamente a pd-1 y metodos de uso
AR117911A2 (es) Anticuerpo anti-158p1d7 o fragmento de unión a antígeno del mismo, conjugado fármaco-anticuerpo, composición farmacéutica y sus usos
BR112021026890A2 (pt) Composições de anticorpo para interromper biofilmes
BR112018071105A2 (pt) conjugado de droga e anticorpo, molécula de ligação, composição farmacêutica e uso
AR104280A1 (es) Terapia de combinación con factores de coagulación y anticuerpos multiespecíficos
PE20181167A1 (es) Proteinas de union triespecificas y/o trivalentes para la prevencion o el tratamiento de la infeccion por vih
AR104213A1 (es) Anticuerpos anti-cd38 como agentes terapéuticos
AR107290A1 (es) ANTICUERPOS PEPTÍDICOS b AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
PE20110797A1 (es) Anticuerpos anti mn
AR065312A1 (es) Nuevos anticuerpos
PE20201171A1 (es) Anticuerpos de cadena pesada que se unen a cd22
BR112024000744A2 (pt) Anticorpos de glicoprotéina spike anti-sars-cov-2 e fragmentos de ligação a antígeno
DOP2025000290A (es) Anticuerpos cd163 o proteínas de unión
PH12022500028A1 (en) Methods for treating or preventing sars-cov-2 infections and covid -19 with anti-sars-cov-2 spike glycoprotein antibodies
AR115192A1 (es) Anticuerpos
BR112019007272A2 (pt) anticorpos anti-ceacam6 e métodos de utilização
PE20180498A1 (es) Inmunoglobulinas conjugadas en cys80
BR112022011350A2 (pt) Composições e métodos para tratamento e prevenção da influenza
AR126001A1 (es) Anticuerpos y composiciones anti-nkg2a
CO2024012622A2 (es) Anticuerpos capaces de unirse a la proteína de la espícula de coronavirus sars-cov-2